Erectile Dysfunction Drugs might help Treat Oesophageal Cancer, Study Finds

Erectile dysfunction drugs could assist treat oesophageal cancer, research study discovers

22 June 2022

An active ingredient in impotence medication may assist deal with cancer, a research study has found.

Southampton researchers found the PDE5 inhibitors in the medication helped penetrate the barrier of cells around tumours, enabling chemotherapy drugs to reach cancer cells.

One in 10 patients presently makes it through the disease, which is discovered anywhere in the gullet, for 10 years or more.

The study was funded by Cancer Research UK. The next phase is a scientific trial.

Prof Tim Underwood, lead author of the research study, said the discovery could enhance these survival rates.

He said a cell known as the cancer-associated fibroblast, responsible for injury healing, might be targeted with the inhibitors.

“It’s been used throughout the world in countless doses,” he discussed. “It’s safe, and we applied it to cancer.”

He added it was to the researchers “wonder and surprise and pleasure” that the drug had an impact.

“We need to put this into a clinical trial where we attempt the drug type along with chemotherapy to see if it makes the chemotherapy more efficient,” he said.

“The preliminary work suggests it must do, and if it does and if it’s safe, and it enhances outcomes of chemotherapy, then it could be truly considerable for the patients I take care of.”

The study was brought out utilizing tumours from eight cancer clients, with more tests done on mice.

Chemotherapy only helps 20% of oesophageal cancer patients in a substantial method, he said.

“If this drug mix even enhances it by a little amount, we’re truly going to assist a big number of people every year to respond better and live longer.”

Researchers at Southampton University Hospitals say that the usual results of erectile dysfunction condition drugs need extra stimulation, so would not affect cancer clients in the same method.

Prof Underwood said the primary adverse effects would be “a bit of headache, a little flushing”.

Terry Daly, from Aldershot, Hampshire, is among the 9,500 people identified with oesophageal cancer in the UK every year.

It typically goes unnoticed in the early phases, with Mr Daly discovering it was hard to swallow his food and he wound up regurgitating it.

He is soon to go through another round of chemotherapy, and stated if he had the option to take the brand-new treatment he would have “taken it with both hands”.

“The research study that is being done is absolutely fantastic,” he said.

“It is just incredible that there are people out there happy to spend their lives just looking for a treatment, so that people can proceed with their everyday lives and not need to go through all this things.

“You can’t thank these people enough for what they’re doing.”

The five-year research study has actually been funded by Cancer Research UK and the Medical Research Council.

A clinical trial is expected within the next 18 months and if successful, it is hoped new treatments based upon this research might be used within 10 years.

Follow BBC South on Facebook, external, Twitter, external, or Instagram, external. Send your story ideas to south.newsonline@bbc.co.uk, external.

Related topics

Aldershot

Southampton

Cancer

We had the exact same cancer as Andy Goram

31 May 2022

Lorry driver’s ‘ticking time-bomb’ cancer gene

20 June 2022

Related internet links

Cancer Research UK

University Hospital Southampton

Institute of Developmental Sciences – University of Southampton

What is oesophageal cancer? – NHS

The BBC is not responsible for the material of external sites.